` BIIB (Biogen Inc) vs S&P 500 Comparison - Alpha Spread

BIIB
vs
S&P 500

Over the past 12 months, BIIB has underperformed S&P 500, delivering a return of -46% compared to the S&P 500's 12% growth.

Stocks Performance
BIIB vs S&P 500

Loading

Performance Gap
BIIB vs S&P 500

Loading
BIIB
S&P 500
Difference

Performance By Year
BIIB vs S&P 500

Loading
BIIB
S&P 500
Add Stock

Competitors Performance
Biogen Inc vs Peers

S&P 500
BIIB
ABBV
AMGN
GILD
VRTX
Add Stock

Biogen Inc
Glance View

Economic Moat
None
Market Cap
18.4B USD
Industry
Biotechnology

Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.

BIIB Intrinsic Value
166.58 USD
Undervaluation 25%
Intrinsic Value
Price
Back to Top